Advertisements

Tavegyl

Quick links to important sections

Tavegyl

Selected form

Advertisements

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Tavegyl

Tavegyl is a synthetic medicinal product fundamentally classified as a first-generation antihistamine, whose primary purpose is to provide relief from the symptoms of allergic reactions and hypersensitivity reactions.

Property Description
Active ingredient Clemastine fumarate
Form Oral tablet, syrup or oral solution, solution for injection
Pharmacological class H₁-receptor antagonist
Common use Relief from symptoms of allergic rhinitis and urticaria
Origin Synthetic compound

What Type of Medicine is Tavegyl and What is its Purpose?

Pharmacologically, Tavegyl is defined as an H₁-receptor antagonist, meaning it works by blocking the specific receptors that the body's natural allergy mediator, histamine, activates. This action systematically counters the effects of histamine release, which helps to mitigate discomforts such as widespread itching (pruritus), hives (urticaria), and the common symptoms of allergic rhinitis. The effectiveness of Clemastine in providing symptomatic relief is clinically recognized, assisting in easing discomfort by interrupting the chemical process that causes allergic symptoms. Due to its classification as a first-generation agent, Tavegyl also possesses a characteristic sedative effect and notable anticholinergic activity, differentiating its overall profile from newer, non-sedating antihistamines, making it a distinct option in the therapeutic landscape.


Clemastine Fumarate: The Active Ingredient and Forms

The central component of Tavegyl is the active chemical substance, Clemastine, typically formulated as Clemastine fumarate, which is a synthetic compound derived from the ethanolamine chemical class. This indicates the drug's composition is based on a precisely manufactured chemical entity. As a single-ingredient product, the entire therapeutic focus is dedicated solely to the H₁-receptor antagonism provided by the Clemastine. Tavegyl's comprehensive range of forms, including the standard oral tablet, a syrup or oral solution, and a sterile solution for injection intended for parenteral use, distinguishes it, allowing for management across diverse patient settings. This flexibility allows for immediate intervention with the injectable solution for severe systemic reactions, a distinct feature compared to many solely oral-formulated antihistamines.

Regulatory References

  1. MedlinePlus: H1 Blockers
Advertisements

What side effects are possible with Tavegyl?

Possible Side Effects and Safety Information

The safety profile of Tavegyl, which contains clemastine fumarate, is officially documented by regulatory authorities and reflects its classification as a first-generation antihistamine. The adverse effects are broadly categorized by the organ system affected.

The most common adverse reaction is transient drowsiness or sedation, which occurs relatively frequently. This central nervous system effect is a key characteristic of the drug's safety profile.

System-Organ Classes and Documented Adverse Reactions

Adverse reactions listed in regulatory documents span multiple physiological systems, including:

  • Nervous System: Confusion, dizziness, disturbed coordination, irritability, and, in rare instances, convulsions.
  • Gastrointestinal System: Dryness of the mouth, nose, and throat (a common anticholinergic effect), epigastric distress, nausea, and constipation.
  • Cardiovascular System: Hypotension, palpitations, and tachycardia.
  • Hematologic System: Rare but serious adverse reactions, including agranulocytosis and hemolytic anemia.
  • General: Anaphylactic shock is listed as a potential, serious adverse reaction.

Population-Specific Safety Considerations

Regulatory labeling specifies safety constraints for certain groups. The use of clemastine fumarate is contraindicated in newborn or premature infants and in nursing mothers due to the potential for serious adverse reactions. Elderly patients (approximately 60 years or older) are noted to be more susceptible to adverse effects such as dizziness, sedation, and hypotension.

Furthermore, the drug's safety profile notes that its effects are additive when used with alcohol and other central nervous system depressants.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with clemastine fumarate (Tavegyl) may result in severe manifestations that require immediate medical attention. The officially documented clinical signs are highly variable, often presenting a biphasic pattern involving the Central Nervous System (CNS).

Initially, CNS effects may include depression, ranging from drowsiness to coma. This can transition to stimulation, characterized by excitement, hallucinations, tremors, and hyperreflexia. Anticholinergic signs are also noted, such as dry mouth, fixed, dilated pupils, flushing of the face, and fever.

Severe Outcomes and Emergency Action

The regulatory labeling explicitly documents severe, life-threatening outcomes, including convulsions (seizures), cardiovascular collapse, and cardio-respiratory arrest. Deaths are reported, particularly in infants and children, who are also documented as having an increased likelihood of CNS stimulation. The severity of these manifestations dictates that urgent medical attention must be sought immediately.

Management is primarily symptomatic and supportive, as no specific antidote is known for acute overdose. Official procedures described in regulatory texts include securing the airway, providing mechanical support of respiration if needed, and employing measures such as gastric lavage and the use of activated charcoal to manage exposure.

Advertisements

Therapeutic Uses of Tavegyl

Main Uses and Benefits of Tavegyl

Tavegyl is an antihistamine medication containing the active ingredient clemastine. It is primarily used to manage symptoms associated with allergic reactions by blocking the effects of histamine, a substance produced by the body during an immune response to allergens.

Relief of Respiratory Allergy Symptoms

The medication is commonly used to alleviate symptoms of upper respiratory allergies, such as allergic rhinitis (hay fever). It helps reduce the following symptoms:

  • Sneezing
  • Runny nose (rhinorrhea)
  • Itchy, watery eyes
  • Itching of the nose or throat

Management of Skin Allergic Reactions

Tavegyl is also indicated for the treatment of various allergic skin conditions. It is effective in reducing the discomfort associated with localized inflammatory responses. Key applications include:

  • Urticaria (Hives): It helps reduce the swelling, redness, and itching associated with hives.
  • Dermatosis: It provides relief from itching (pruritus) related to various types of eczema and dermatitis.
  • Insect Bites and Stings: It can manage the localized allergic swelling and irritation following insect contact.

Benefits of Clemastine

As a first-generation antihistamine, clemastine is characterized by its ability to provide relief from acute symptoms. Some of the therapeutic benefits include:

  • Reduction of Capillary Permeability: By blocking H1 receptors, it helps prevent the leakage of fluids into tissues, which reduces swelling and congestion.
  • Anti-Pruritic Effect: It is specifically recognized for its efficacy in controlling intense itching, which can improve the quality of life for patients with dermatological allergies.
  • Duration of Action: It typically provides a sustained effect, helping to manage symptoms over several hours.

Regulatory References

  1. NIH DailyMed drug information
Advertisements

Eligibility and Restrictions for Use

The eligibility for Tavegyl (clemastine fumarate) is strictly defined by regulatory documents, listing populations that are prohibited from use and those who require significant caution.

Contraindicated Populations

Use is contraindicated in several groups due to a higher risk of adverse effects, including newborn or premature infants and nursing mothers. Tavegyl is also prohibited for patients with known hypersensitivity to the drug and those with lower respiratory tract symptoms such as asthma. It must not be used by patients receiving monoamine oxidase (MAO) inhibitor therapy.

Age-Related Eligibility and Restrictions

The approved use for tablets is generally for patients 12 years of age and older, as safety and efficacy are not established for children under 12. For the oral solution or syrup, use is indicated for children 6 years of age and older. Geriatric patients (approximately 60 years or older) are cautioned due to the increased risk of dizziness, sedation, and hypotension.

Condition-Based Cautions

The medicine should be used with considerable caution in individuals with conditions potentially affected by the drug's anticholinergic properties, including narrow-angle glaucoma, stenosing peptic ulcer, symptomatic prostatic hypertrophy, and bladder neck obstruction. Caution is also advised for patients with cardiovascular disease, hypertension, hyperthyroidism, or underlying liver and/or renal disease.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Tavegyl (clemastine fumarate), as a first-generation antihistamine, has a high potential for additive effects when combined with other substances that cause central nervous system (CNS) depression.


Clinically Significant Interactions

Interacting Product Category Nature of Interaction Clinical Constraint/Mechanism
Alcohol Increased CNS depressant effect Additive sedation, drowsiness, impaired coordination
CNS Depressants (e.g., hypnotics, tranquilizers, sedatives, barbiturates, anti-anxiety agents) Increased CNS depressant effect Use is advised against due to additive sedation and increased risk of adverse effects.
Monoamine Oxidase (MAO) Inhibitors Intensified anticholinergic effects Prolongs and intensifies the drying (anticholinergic) effects of clemastine. This combination is generally contraindicated.

Other Interaction Notes

The effects of Tavegyl, including drowsiness, dizziness, and blurred vision, may be significantly increased by concurrent use of the medicinal products listed above. Patients should avoid engaging in activities requiring complete mental alertness, such as driving or operating heavy machinery, when combined with interacting agents. Its use is also contraindicated in nursing mothers due to the higher risk of adverse reactions for infants, particularly newborns and premature infants. Careful consideration by a healthcare professional is required when Tavegyl is used with any medicine or product that affects the CNS or has anticholinergic properties.

Advertisements

Mechanism of Action

How Tavegyl Works

Tavegyl (clemastine) primarily acts by modulating key signaling pathways mediated by histamine and acetylcholine. The mechanism operates across two main pharmacodynamic domains: primary histamine receptor blockade and secondary cholinergic system influence.

Primary Action: Blocking Histamine H1 Receptors

The core molecular function is its action as a competitive antagonist on the Histamine H1 receptors. By physically occupying these receptor sites, clemastine effectively suppresses signaling events typically initiated by the endogenous mediator histamine. This modification of an early molecular step results in reduced activation of downstream pathways driven by high local concentrations of the mediator, thereby modifying the cellular activity state within the targeted physiological pathways.

Secondary Action: Modulation of Cholinergic Pathways

Clemastine also engages mechanisms that influence muscarinic cholinergic receptor systems, where it acts as an antagonist. This secondary action modulates signaling activity within defined peripheral pathways. This interaction contributes to observable physiological adjustments, specifically decreasing the activity of secretory processes in exocrine glands, which contributes to the full spectrum of observed pharmacological responses.

Advertisements

Dosage and Administration Information

How to Use Tavegyl (Clemastine Fumarate) Tablets

The following are the administration instructions for Tavegyl tablets (clemastine 1 mg as clemastine fumarate 1.34 mg).

Administration and Timing

Route of administration: Tavegyl tablets are for oral use only. The tablet should be swallowed whole with water.

Timing: The tablet must be taken before meals. The standard frequency of use is twice daily—once in the morning and once in the evening—unless otherwise directed by a healthcare provider. Dosage should be individualized based on patient response.

Dosage by Age Group

The dosage for Tavegyl must be followed according to age:

Age Group Clemastine Dosage Frequency Pattern
Adults and adolescents (over 12 years) 1 mg (as 1.34 mg clemastine fumarate) Twice daily (morning and evening)
Children (6 to 12 years) 0.5 mg (as 0.67 mg clemastine fumarate) Twice daily (morning and evening)
Children under 6 years Tablets are not recommended. Not applicable

For adults and adolescents, the dosage may be adjusted by a clinician up to a maximum daily intake, but the maximum dosage for self-medication is 1.34 mg every 12 hours. No specific instruction is provided regarding a missed dose.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tavegyl

The research evidence for Clemastine fumarate (Tavegyl) is derived from trials and regulatory assessments that focus on its classification as a first-generation H₁-antihistamine and its evaluation in research contexts involving acute allergic manifestations. These studies monitored how symptoms changed over defined time intervals in observed individuals.


Evidence Summary for Allergic Rhinitis and Hay Fever Symptoms

Research was conducted exploring how symptoms change over time in conditions characterized by fluctuating or episodic symptoms, such as allergic rhinitis, primarily utilizing short-term, randomized, placebo-controlled trials. Studies focused on measuring outcomes related to physical discomfort in the nasal and ocular areas.

Researchers examined specific patient-reported outcomes describing perceived discomfort, such as the frequency of sneezing and the presence of rhinorrhea (runny nose). In these studies, findings describe patterns observed in the symptoms of the participating populations over short observation periods, often compared to outcomes in those who received a placebo. Furthermore, some research explored the drug's effect in pharmacodynamic models by monitoring the observed changes in the wheal and flare reaction in the skin, which is relevant in evidence describing how symptoms are measured.


Evidence Summary for Urticaria and Allergic Skin Manifestations

For conditions associated with acute or disruptive episodes, such as urticaria (hives) and other mild allergic skin manifestations, Clemastine fumarate was studied for its evaluation in research exploring outcomes linked to inflammatory or irritative states. Research explored outcomes related to the appearance of wheals and the patient-reported severity of pruritus (itching).

The evidence, including early clinical investigations and objective pharmacodynamic studies, contributes to the overall documentation of symptom patterns in this context. These studies monitored how symptoms evolved in adult and pediatric populations during the study period. Findings describe patterns observed in the studies, which contribute to the broader understanding of how patients reported their experience during acute episodes.


Understanding Research Gaps and Uncertainties

The majority of the core evidence for the approved uses of Clemastine fumarate is derived from short-term trials, meaning that the long-term effects are not well characterized. Research examining long-term symptom patterns related to continuous use is less established in the foundational evidence base.

Evidence is limited regarding the medicine's profile in direct comparison to many newer, non-sedating H₁-antihistamines using contemporary research designs. Data are also limited for certain groups, particularly those with complex comorbidities or very young children (under 6 years old), and findings describe group patterns, not individual predictions. Research provides context but not individual predictions, and the available evidence highlights what is known—and what is still uncertain—about this medicine's evidence landscape.

Key Studies & References

  1. NIH DailyMed Drug Information: Clemastine Fumarate Tablets
  2. MedlinePlus: H1 Blockers
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Tavegyl (FAQ)


Q: Does Tavegyl cause sleepiness or drowsiness?

A: Yes, regulatory documents list transient drowsiness as the most common adverse reaction associated with clemastine fumarate. Official information indicates that activities requiring complete mental alertness may need to be avoided due to the risk of drowsiness.


Q: What is the main ingredient in Tavegyl?

A: The active ingredient in Tavegyl tablets is clemastine fumarate. This is the substance that acts to modify allergic responses in the body.


Q: Is it normal to feel dry mouth after taking Tavegyl?

A: Dryness of the mouth, nose, and throat is a commonly reported adverse reaction associated with this type of antihistamine. This is related to the drug's influence on specific nervous system pathways that control secretory processes.


Q: Can older people (seniors) use Tavegyl?

A: Regulatory information states that clemastine is used with caution in patients approximately 60 years or older. Antihistamines are more likely to cause side effects such as dizziness, sedation, and low blood pressure in elderly patients.


Q: Is Tavegyl suitable for children?

A: Official guidelines indicate that clemastine tablets are generally not recommended for children under 6 years of age. In some regions, safety and effectiveness have not been established for children younger than 12 years of age.


Q: Can I take Tavegyl if I am taking painkillers?

A: Clemastine is a central nervous system (CNS) depressant, and official product information warns that it may have additive depressant effects when combined with other substances that cause CNS depression. Combination use requires consultation with a healthcare professional to assess specific risk.


Q: What do official sources say about taking Tavegyl during pregnancy?

A: According to the official product information, clemastine is classified as Pregnancy Category B. Its use during pregnancy is described as appropriate only when a healthcare professional assesses that the benefit is greater than the potential risk.


Q: Are there major interactions between Tavegyl and medications for anxiety?

A: Regulatory documents mention that caution is warranted. Clemastine may cause increased CNS depressant effects when combined with anti-anxiety agents, tranquilizers, or other sedatives, potentially leading to increased drowsiness or impaired coordination.


Q: Is Tavegyl still available to buy?

A: While the drug is available, the status of the specific brand name product may vary by region. The active drug, clemastine fumarate, is generally available as a generic or branded product.


Q: Is Tavegyl an old type of antihistamine?

A: Yes, official sources classify clemastine fumarate as a first-generation H1 antihistamine. These types of antihistamines are generally known to often cause sedation.


Q: How quickly does Tavegyl start working after taking it?

A: According to official clinical pharmacology data, peak concentrations of the drug in the blood are typically reached within 2 to 4 hours after a single oral dose. The maximal anti-allergic effect is usually seen after 5 to 7 hours.


Q: How long do the effects of Tavegyl typically last?

A: Studies and official information indicate that the anti-allergic effect often persists for 10 to 12 hours. In some individuals, the effects may last for up to 24 hours.


Q: Can Tavegyl be used for a skin rash or hives?

A: Official documentation indicates that clemastine is approved for the relief of mild, uncomplicated allergic skin issues. This includes manifestations of urticaria (hives) and angioedema.


Q: Is Tavegyl effective for year-round allergies?

A: Clemastine is indicated for the relief of symptoms associated with allergic rhinitis. This general term applies to both seasonal allergies (like hay fever) and perennial (year-round) allergies.


Q: Are there any known issues with taking Tavegyl if I have kidney problems?

A: Regulatory information states that clemastine is used with caution in patients with kidney problems. Due to the potential for the drug to accumulate in the body, official sources note that lower initial dosages may be needed.


Q: Is Tavegyl considered a sedating antihistamine?

A: Yes, official product descriptions classify clemastine fumarate as an antihistamine with noted sedative side effects. This means it is likely to cause sleepiness.


Q: Is there a generic version of Tavegyl?

A: Yes, the active drug, clemastine fumarate, is widely available as a generic product in various regions.


Q: What are the most common side effects listed for Tavegyl?

A: The most frequent adverse reactions reported in official sources are transient drowsiness, followed by dryness of the mouth/nose/throat, dizziness, and headache.


Q: Can I take Tavegyl if I have high blood pressure?

A: Clemastine is used with caution in patients with pre-existing hypertension (high blood pressure) or other cardiovascular disease. Official guidance indicates that its use requires discussion with a healthcare provider.


Q: Is Tavegyl safe to use while breastfeeding?

A: Use in nursing mothers is contraindicated by the manufacturer. This is due to the higher risk of adverse effects for infants, particularly newborns and premature infants, from antihistamines.


Q: Can Tavegyl interact with herbal supplements?

A: The drug label primarily warns against use with CNS depressants and MAO Inhibitors. Consultation with a healthcare professional is necessary, as some herbal supplements may also have CNS depressant effects.


Q: What types of allergic reactions is Tavegyl approved to treat?

A: Official information states clemastine is approved for symptoms of allergic rhinitis (e.g., sneezing, runny nose, itchy eyes) and mild allergic skin manifestations like hives (urticaria).


Q: Is Tavegyl available without a prescription?

A: Clemastine is available as both prescription and non-prescription (over-the-counter) products. The availability status often depends on the specific dosage and formulation authorized in a particular region.


Q: Does Tavegyl cause stomach upset?

A: Gastrointestinal side effects, including epigastric distress (upper stomach discomfort), anorexia, nausea, and vomiting, have been reported in official adverse reaction listings.


Q: How should I store Tavegyl tablets?

A: Official guidance specifies that clemastine tablets are typically stored at controlled room temperature (e.g., 20 C to 25 C) and protected from light and moisture.


Q: Can Tavegyl be taken with antacids?

A: Antacids are not listed as a contraindication or major interaction in the drug label’s dedicated interaction section. As with any non-listed drug combination, consultation with a healthcare professional is appropriate for concerns.


Q: Is Tavegyl an antihistamine of the first generation?

A: Yes, official sources classify clemastine fumarate as a first-generation H1 antihistamine.


Q: What kind of research evidence supports the use of Tavegyl?

A: The use is supported by pharmacological studies that demonstrate the drug's antihistaminic effects are maximal within 5 to 7 hours after administration and persist for 10 to 12 hours.


Q: Can people with glaucoma take Tavegyl?

A: Clemastine is generally contraindicated or used with considerable caution in patients with narrow-angle glaucoma. This is due to the drug's anticholinergic effects, which can worsen the condition.


Q: Is Tavegyl known to affect mood?

A: Reported adverse reactions from the nervous system may include changes in mood such as excitement, nervousness, irritability, and euphoria. Stimulation is considered particularly likely in children.


Q: Are there any specific warnings about Tavegyl for people with heart conditions?

A: Regulatory information states that clemastine is used with caution in patients with pre-existing cardiovascular disease. Rare cardiovascular side effects such as low blood pressure (hypotension) and fast heart rate (tachycardia) have been reported.


Q: How soon after stopping Tavegyl does it leave the body?

A: According to official clinical data, the terminal elimination half-life of clemastine is approximately 21.3 hours. This is the time it takes for the concentration of the drug in the body to be reduced by half.

Advertisements

How should Tavegyl be stored and disposed of?

How to Store and Dispose of Tavegyl?

Clemastine fumarate (Tavegyl) must be stored and disposed of according to strict official regulatory instructions to maintain quality and ensure safety.


Storage Requirements

Requirement Type Official Condition
Temperature Store at controlled room temperature, specifically 20mathrmC to 25mathrmC (68mathrmF to 77mathrmF).
Protection Store away from excess heat and excess moisture. The product must not be frozen.
Packaging Keep the medicine in its original container and keep the container tightly closed.
Safety Store out of the sight and reach of children.

Disposal Instructions

Official disposal protocols prioritize using a drug take-back program for unused or expired product. If a take-back option is unavailable, the medicine may be removed from its container, mixed with an undesirable substance (e.g., dirt or coffee grounds), and placed in a sealed bag for disposal in household trash. Medicines must not be disposed of via wastewater or sewage.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tavegyl found in:

A-Z Index: